A review of nebulized drug delivery in COPD

References

• BarjaktarevicIZArredondoAFCooperCBPositioning new pharmacotherapies for COPDInt J Chron Obstruct Pulmon Dis2015101427144226244017
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD) [web-page on the Internet]Global Strategy for Diagnosis, Management, and Prevention of COPD –2016 Available from: http://goo.gl/ItQL3aAccessed May 4, 2016
   Google Scholar
• DolovichMBAhrensRCHessDRAmerican College of Chest Physicians; American College of Asthma, Allergy, and ImmunologyDevice selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and ImmunologyChest2005127133537115654001
   PubMed Web of Science ®Google Scholar
• RamFSBrocklebankDMMuersMWrightJJonesPWPressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20021CD00217011869627
   PubMedGoogle Scholar
• TurnerMOPatelAGinsburgSFitzGeraldJMBronchodilator delivery in acute airflow obstruction. A meta-analysisArch Intern Med199715715173617449250235
   PubMedGoogle Scholar
• DhandRDolovichMChippsBMyersTRRestrepoRFarrarJRThe role of nebulized therapy in the management of COPD: evidence and recommendationsCOPD201291587222292598
   PubMedGoogle Scholar
• BoniniMUsmaniOSThe importance of inhaler devices in the treatment of COPDCOPD Res Pract20151119
   Google Scholar
• LavoriniFCorriganCJBarnesPJAerosol Drug Management Improvement TeamRetail sales of inhalation devices in European countries: so much for a global policyRespir Med201110571099110321489771
   PubMed Web of Science ®Google Scholar
• SharafkhanehAWolfRAGoodnightSHananiaNAMakeBJTashkinDPPerceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectivesCOPD201310448249223875742
   PubMedGoogle Scholar
• BartaSKCrawfordARobertsCMSurvey of patients’ views of domiciliary nebuliser treatment for chronic lung diseaseRespir Med200296637538112117035
   PubMed Web of Science ®Google Scholar
• QaseemAWiltTJWeinbergerSEAmerican College of PhysiciansAmerican College of Chest PhysiciansAmerican Thoracic SocietyEuropean Respiratory SocietyDiagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory SocietyAnn Intern Med2011155317919121810710
   PubMed Web of Science ®Google Scholar
• AngelisNPorpodisKZarogoulidisPAirway inflammation in chronic obstructive pulmonary diseaseJ Thorac Dis20146suppl 1S167S17224672691
   PubMed Web of Science ®Google Scholar
• VosTFlaxmanADNaghaviMYears lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010Lancet201238098592163219623245607
   PubMed Web of Science ®Google Scholar
• LozanoRNaghaviMForemanKGlobal and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010Lancet201238098592095212823245604
   PubMed Web of Science ®Google Scholar
• LandisSHMuellerovaHManninoDMContinuing to confront COPD international patient survey: methods, COPD prevalence, and disease burden in 2012–2013Int J Chron Obstruct Pulmon Dis2014959761124944511
   PubMed Web of Science ®Google Scholar
• ManninoDMBuistASGlobal burden of COPD: risk factors, prevalence, and future trendsLancet2007370958976577317765526
   PubMed Web of Science ®Google Scholar
• Lung.org [webpage on the Internet]American Lung Association COPD fact sheet [updated 2011]. Available from: http://www.lung.org/lung-disease/copd/resources/facts-figures/COPD-Fact-Sheet.htmlAccessed March 3, 2016
   Google Scholar
• Nhlbi.nih.gov [webpage on the Internet]National Heart Lung and Blood Institute. Morbidity and mortality: 2012 chart book on cardiovascular, lung, and blood diseases Available from: http://www.nhlbi.nih.gov/resources/docs/cht-book.htmAccessed March 3, 2016
   Google Scholar
• AkinbamiLJLiuXChronic obstructive pulmonary disease among adults aged 18 and over in the United States, 1998–2009NCHS Data Brief20116318
   Google Scholar
• CDC.gov Centers for Disease Control and Prevention. National Center for Health StatisticsData brief 63: chronic obstructive pulmonary disease among adults aged 18 and over in the United States, 1998–2009 Available from: http://www.cdc.gov/nchs/data/databriefs/db63_tables.pdf#2Accessed March 4, 2016
   Google Scholar
• QuinetPYoungCAHeritierFThe use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary diseaseAnn Phys Rehabil Med2010532697620018583
   PubMedGoogle Scholar
• TaffetGEDonohueJFAltmanPRConsiderations for managing chronic obstructive pulmonary disease in the elderlyClin Interv Aging20149233024376347
   PubMed Web of Science ®Google Scholar
• MahlerDAWatermanLAWardJGiffordAHComparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rateJ Aerosol Med Pulm Drug Deliv201427210310923745526
   PubMed Web of Science ®Google Scholar
• CelliBRUpdate on the management of COPDChest200813361451146218574288
   PubMed Web of Science ®Google Scholar
• Mayoclinic.org [webpage on the Internet]Diseases and conditions: COPD: treatments and drugs Available from: http://www.mayoclinic.org/diseases-conditions/copd/basics/treatment/con-20032017Accessed March 18, 2016
   Google Scholar
• BarronsRPegramABorriesAInhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary diseaseAm J Health Syst Pharm201168131221123221690428
   PubMed Web of Science ®Google Scholar
• DekhuijzenPNBjermerLLavoriniFNinaneVMolimardMHaughneyJGuidance on handheld inhalers in asthma and COPD guidelinesRespir Med2014108569470024636812
   PubMed Web of Science ®Google Scholar
• MelaniASBonaviaMCilentiVGruppo Educazionale Associazione Italiana Pneumologi OspedalieriInhaler mishandling remains common in real life and is associated with reduced disease controlRespir Med2011105693093821367593
   PubMed Web of Science ®Google Scholar
• NewmanSPInhaler treatment options in COPDEur Respir Rev20051496102108
   Google Scholar
• DolovichMBDhandRAerosol drug delivery: developments in device design and clinical useLancet201137797701032104521036392
   PubMed Web of Science ®Google Scholar
• BerlinskiAAssessing new technologies in aerosol medicine: strengths and limitationsRespir Care2015606833847 discussion 847–84926070578
   PubMed Web of Science ®Google Scholar
• RauJLPractical problems with aerosol therapy in COPDRespir Care200651215817216441960
   PubMed Web of Science ®Google Scholar
• RubinBKPediatric aerosol therapy: new devices and new drugsRespir Care201156914111421 discussion 1421–142321944688
   PubMed Web of Science ®Google Scholar
• AriAJet, ultrasonic, and mesh nebulizers: an evaluation of nebulizers for better clinical outcomesEurasian J Pulmonol20141617
   Google Scholar
• ZemanKTiffinNEfficiency of portable jet nebulizer systems using budesonideAm J Respir Crit Care Med2010181A1347
   Web of Science ®Google Scholar
• LenneyWEdenboroughFKhoPKovarikJMLung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjectsJ Cyst Fibros201110191420884302
   PubMed Web of Science ®Google Scholar
• GoodmanNMorganMNikanderKHinchSCoughlinSEvaluation of patient-reported outcomes and quality of life with the I-neb AAD system in patients with chronic obstructive pulmonary diseaseJ Aerosol Med Pulm Drug Deliv201023suppl 1S61S7020373911
   PubMed Web of Science ®Google Scholar
• AndersonPUse of Respimat® Soft Mist™ Inhaler in COPD patientsInt J Chron Obstruct Pulmon Dis20061325125918046862
   PubMedGoogle Scholar
• MeyerKCCOPD 2013: an update on treatment and newly approved medications for pharmacistsJ Am Pharm Assoc (2003)2013536e219e229 quiz e230-124185438
   PubMed Web of Science ®Google Scholar
• LohCHDonohueJFOharJAReview of drug safety and efficacy of arformoterol in chronic obstructive pulmonary diseaseExpert Opin Drug Saf201514346347225563342
   PubMed Web of Science ®Google Scholar
• DonohueJFHananiaNAMakeBOne-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPDChest201414661531154225451347
   PubMed Web of Science ®Google Scholar
• KingPRole of arformoterol in the management of COPDInt J Chron Obstruct Pulmon Dis20083338539118990965
   PubMedGoogle Scholar
• HanrahanJPHananiaNACalhounWJSahnSASciarappaKBaumgartnerRAEffect of nebulized arformoterol on airway function in COPD: results from two randomized trialsCOPD200851253418259972
   PubMedGoogle Scholar
• BaumgartnerRAHananiaNACalhounWJSahnSASciarappaKHanrahanJPNebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trialClin Ther200729226127817472819
   PubMed Web of Science ®Google Scholar
• TashkinDPDonohueJFMahlerDAEffects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPDRespir Med2009103451652419208459
   PubMed Web of Science ®Google Scholar
• GrossNJNelsonHSLapidusRJFormoterol Study GroupEfficacy and safety of formoterol fumarate delivered by nebulization to COPD patientsRespir Med2008102218919718363201
   PubMed Web of Science ®Google Scholar
• KottakisJCioppaGDCreemersJFaster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical studyCan Respir J20029210711511972164
   PubMedGoogle Scholar
• SutherlandERBrazinskySFeldmanGMcGintyJTomlinsonLDenis-MizeKNebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDICurr Med Res Opin200925365366119232039
   PubMed Web of Science ®Google Scholar
• TashkinDPHananiaNAMcGintyJDenis-MizeKChaudryINebu-lized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary diseaseAdv Ther200926111024103419953349
   PubMed Web of Science ®Google Scholar
• HananiaNABootaAKerwinETomlinsonLDenis-MizeKEfficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: results from a 6-week, randomized, placebo-controlled, clinical trialDrugs20096991205121619537837
   PubMed Web of Science ®Google Scholar
• TashkinDPLittnerMAndrewsCPTomlinsonLRinehartMDenis-MizeKConcomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trialRespir Med2008102447948718258423
   PubMed Web of Science ®Google Scholar
• DeeksEDOlodaterol: a review of its use in chronic obstructive pulmonary diseaseDrugs201575666567325773742
   PubMed Web of Science ®Google Scholar
• Boehringer IngelheimNewly published head-to-head data show stiolto™ respimat® (tiotropium bromide and olodaterol) improved lung function across range of measures [press release]Boehringer Ingelheim201629 Available from: https://goo.gl/VpstiJAccessed September 28, 2016
   Google Scholar
• FeldmanGJBernsteinJAHamiltonANivensMCKorduckiLLaForceCThe 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studiesSpringerplus2014341925187881
   PubMedGoogle Scholar
• KeatingGMTiotropium Respimat® soft mist inhaler: a review of its use in chronic obstructive pulmonary diseaseDrugs201474151801181625300412
   PubMed Web of Science ®Google Scholar
• HochrainerDHolzHKreherCScaffidiLSpallekMWachtelHComparison of the aerosol velocity and spray duration of Respimat soft mist inhaler and pressurized metered dose inhalersJ Aerosol Med200518327328216181002
   PubMedGoogle Scholar
• IaconoPVelicitatPGuemasELeclercVThebaultJJImproved delivery of ipratropium bromide using Respimat (a new soft mist inhaler) compared with a conventional metered dose inhaler: cumulative dose response study in patients with COPDRespir Med200094549049510868713
   PubMed Web of Science ®Google Scholar
• DahlRCalverleyPMAnzuetoASafety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trialBMJ Open2015512e009015
   PubMed Web of Science ®Google Scholar
• BarrRGBourbeauJCamargoCARamFSInhaled tiotropium for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20052CD00287615846642
   PubMed Web of Science ®Google Scholar
• ZuWallackRAllenLHernandezGTingNAbrahamsREfficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: results of two randomized, double-blind, active-controlled studiesInt J Chron Obstruct Pulmon Dis201491133114425342898
   PubMed Web of Science ®Google Scholar
• FergusonGTFlezarMKornSEfficacy of tiotropium + olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysisAdv Ther201532652353626112656
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• SinghDFergusonGTBolitschekJTiotropium + olodaterol shows clinically meaningful improvements in quality of lifeRespir Med2015109101312131926320402
   PubMed Web of Science ®Google Scholar
• DattaDVitaleALahiriBZuWallackRAn evaluation of nebulized levalbuterol in stable COPDChest2003124384484912970007
   PubMed Web of Science ®Google Scholar
• NairSThomasEPearsonSBHenryMTA randomized controlled trial to assess the optimal dose and effect of nebulized albuterol in acute exacerbations of COPDChest20051281485416002915
   PubMed Web of Science ®Google Scholar
• BorkowskiJCraderMNebulized albuterol versus levalbuterol in pediatric and adult patients: a reviewFormulary200944108118
   Google Scholar
• TruittTWitkoJHalpernMLevalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthmaChest2003123112813512527613
   PubMed Web of Science ®Google Scholar
• Ipratropium BromideIpratropium bromide solution [prescribing information]FLCobalt Laboratories Available from: https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=lf69f100f-c766-490f-9143-5e8e0c8cb7c9&type=pdf&name=lf69f100f-c766-490f-9143-5e8e0c8cb7c9Accessed March 13, 2016
   Google Scholar
• DuoNeb^® (Ipratropium Bromide 0.5 mg/Albuterol Sulfate 3.0 mg*) inhalation solution [prescribing information]CADey Pharma, L.P Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020950s037lbl.pdfAccessed February 23, 2016
   Google Scholar
• The COMBIVENT Inhalation Solution Study GroupRoutine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study GroupChest19971126151415219404747
   PubMed Web of Science ®Google Scholar
• YorkJMSmeedingJBrookRAHoehlerFKleinGLExploratory economic evaluation of patients with COPD on a combination product versus individual components (ipratropium bromide and albuterol)Adv Ther200724475777117901025
   PubMed Web of Science ®Google Scholar
• Combivent^® Respimat^® (ipratropium bromide and albuterol) inhalation spray [prescribing information]1996 Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Combivent%20Respimat/CMVTRSPT.pdfAccessed May 24, 2016
   Google Scholar
• LeakerBRBarnesPJJonesCRTutuncuASinghDEfficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary diseaseBr J Clin Pharmacol201579349250025243340
   PubMed Web of Science ®Google Scholar
• FogartyCDunnKSinghDTutuncuAKerwinECardiovascular safety of nebulized glycopyrrolate (SUN-101) compared with tiotropium, ipratropium and placebo in patients with COPDClin Res2013234
   Google Scholar
• Sunovion Respiratory Development IncRandomized, double-blind, placebo-controlled, parallel-group, multicenter, efficacy and safety trial of 12 weeks of treatment with nebulized SUN-101 in patients with COPD: Golden-3 (glycopyrrolate for obstructive lung disease via electronic nebulizer) Available from: https://clinicaltrials.gov/ct2/show/NCT2347761?term=NLMidentifier&rank=1. NCT2347761.NLM identifier: NCT2347761Accessed March 13, 2016
   Google Scholar
• Sunovion Respiratory Development IncA randomized, double-blind, placebo-controlled, parallel-group, multicenter, efficacy and safety trial of 12 weeks of treatment with nebulized SUN-101 in patients with COPD: Golden-4 (glycopyrrolate for obstructive lung disease via electronic nebulizer) Available from: https://clinicaltrials.gov/ct2/show/NCT2347774?term=NCT2347774&rank=1. NLM identifier: NCT2347774Accessed March 13, 2016
   Google Scholar
• Sunovion Respiratory Development IncA randomized, open-label, active-controlled, parallel-group, multicenter, long-term safety trial of treatment with nebulized SUN-101 in patients with COPD: Golden-5 (glycopyrrolate for obstructive lung disease via electronic nebulizer) Available from: https://clinicaltrials.gov/ct2/show/NCT2276222?term=NCT2276222&rank=1. NLM identifier: NCT2276222Accessed March 13, 2016
   Google Scholar
• GrossNThe COPD pipeline, XXVIIIJ COPD Found201523259263
   Google Scholar
• Pulido-RiosMTMcNamaraAObedencioGPIn vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal modelsJ Pharmacol Exp Ther2013346224125023685545
   PubMed Web of Science ®Google Scholar
• LoANichollsAJHaumannBMoranEJBourdetDLA population PK model of once-daily TD-4208, a nebulized long-acting muscarinic antagonist (LAMA) in patients with chronic obstructive pulmonary disease (COPD)Am J Respir Crit Care Med2015191A5764 Abstract
   Web of Science ®Google Scholar
• NichollsAJBarnesCYatesWMoranEJSinghDA randomized, crossover, 7-day study of once-daily TD-4208, a long-acting muscarinic antagonist, in subjects with COPDAm J Respir Crit Care Med2014189A6003 Abstract
   Web of Science ®Google Scholar
• HaumannBKNichollsAJBarnesCBourdetDLMoranEJDose-ranging study of once-daily TD-4208, an inhaled long-acting muscarinic antagonist (LAMA) in patients with chronic obstructive pulmonary disease (COPD)Am J Respir Crit Care Med2015191A5750 Abstract
   Web of Science ®Google Scholar
• Theravance Biopharma R & D, IncA phase 3, 12-week, randomized, double-blind placebo-controlled parallel group study of nebulized TD-4208 in subjects with chronic obstructive pulmonary disease Available from: https://goo.gl/ab2VxL?term=NLMidentifier&rank=NCT2459080. NLM identifier: NCT2459080Accessed March 13, 2016
   Google Scholar
• Theravance Biopharma R & D, IncA phase 3, 12-week, randomized, double-blind placebo-controlled parallel group study of nebulized TD-4208 in subjects with chronic obstructive pulmonary disease Available from: https://goo.gl/fPyjfM?term=NLMidentifier&rank=NCT2512510. NLM identifier: NCT2512510Accessed March 13, 2016
   Google Scholar
• Theravance Biopharma R & D, IncA phase 3, 52-week, random-ized, active-controlled parallel group study to evaluate the safety and tolerability of nebulized TD-4208 in subjects with chronic obstructive pulmonary disease Available from: https://goo.gl/83EjwX?term=NLMidentifier&rank=NCT2518139. NLM identifier: NCT2518139Accessed March 13, 2016
   Google Scholar
• TashkinDPKleinGLColmanSSZayedHSchonfeldWHComparing COPD treatment: Nebulizer, metered dose inhaler, and concomitant therapyAm J Med2007120543544117466655
   PubMed Web of Science ®Google Scholar
• BrovanaBrovana medical guide and prescribing information2006 Available from: http://www.brovana.com/brovana-approved-labeling-text.pdfAccessed May 24, 2016
   Google Scholar
• The Global Initiative for Chronic Obstructive Lung DiseaseThe 2016 Global Strategy for Diagnosis, Management, and Prevention of COPD Available from: http://goo.gl/ItQL3aAccessed March 3, 2016
   Google Scholar
• TashkinDPFergusonGTCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseRespir Res2013144923651244
   PubMed Web of Science ®Google Scholar
• CazzolaMSegretiAMateraMGNew developments in the combination treatment of COPD: focus on umeclidinium/vilanterolDrug Des Devel Ther2013712011208
   PubMed Web of Science ®Google Scholar
• AdiHYoungPMTrainiDCo-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalersJ Pharm Pharmacol20126491245125322881437
   PubMed Web of Science ®Google Scholar
• Lechuga-BallesterosDNogaBVehringRCummingsRHDwivediSKNovel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthmaFuture Med Chem20113131703171821942257
   PubMed Web of Science ®Google Scholar
• Bevespi Aerosphere™ (glycopyrrolate and formoterol fumarate) inhalation aerosol, for oral inhalation use [prescribing information]2016Holmes ChapelAventis Pharma LTD Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208294s000lbl.pdfAccessed May 24, 2016
   Google Scholar
• BarnesPJTriple inhalers for obstructive airways disease: will they be useful?Expert Rev Respir Med20115329730021702649
   PubMed Web of Science ®Google Scholar
• LipworthBTriple inhaler therapy for COPDThorax2015701099126092923
   PubMed Web of Science ®Google Scholar
• TrivediRKChendakeDSPatelMCA rapid, stability-indicating RP-HPLC method for the simultaneous determination of formoterol fumarate, tiotropium bromide, and ciclesonide in a pulmonary drug productSci Pharm201280359160323008808
   PubMedGoogle Scholar
• VestboJHurdSSAgustiAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
   PubMed Web of Science ®Google Scholar
• LaubeBLJanssensHMJonghFHDevadasonSGDhandRDiotPWhat the pulmonary specialist should know about the new inhalation therapiesEur Respir J20113761308133121310878
   PubMed Web of Science ®Google Scholar
• GrossNJDonohueJFNebulized formoterol: a review of clinical efficacy and safety in COPDInt J Chron Obstruct Pulmon Dis2010522323220714376
   PubMedGoogle Scholar
• FergusonGTFeldmanGJHofbauerPEfficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014962964524966672
   PubMed Web of Science ®Google Scholar
• van NoordJACornelissenPJAumannJLPlatzJMuellerAFogartyCThe efficacy of tiotropium administered via Respimat soft mist inhaler or HandiHaler in COPD patientsRespir Med20091031222919022642
   PubMed Web of Science ®Google Scholar
• Accuneb^® (albuterol sulfate) inhalation solution [prescribing information] Available from: http://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=fa5ebedb-069c-4a1e-9a25-b6fa957e6c2b&type=pdf&name=fa5ebedb-069c-4a1e-9a25-b6fa957e6c2bAccessed March 13, 2016
   Google Scholar
• Xopenex^® (levalbuterol HCl) inhalation solution [prescribing information] Available from: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=20083Accessed March 13, 2016
   Google Scholar
• Theravance BiopharmaTheravance Biopharma announces positive top-line results from phase 2b dose-ranging study of its investigational LAMA, TD-4208, for the treatment of COPD [press release]. Thera-vance Biopharma; 2014 [September 8] Available from: https://goo.gl/fhudYXAccessed September 28, 2016
   Google Scholar
• KesserKCGellerDENew aerosol delivery devices for cystic fibrosisRespir Care200954675476719467162
   PubMed Web of Science ®Google Scholar